

Anti-Scl-70 ELISA (IgG)


Test instruction

ORDER NO.	ANTIBODIES AGAINST	IG-CLASS	SUBSTRATE	FORMAT
EA 1599-9601 G	Scl-70	IgG	Ag-coated microplate wells	96 x 01 (96)

Indication: Progressive systemic sclerosis.

Principles of the test: The ELISA test kit provides a semiquantitative or quantitative in vitro assay for human autoantibodies of the IgG class against Scl-70 in serum or plasma. The test kit contains microtiter strips each with 8 break-off reagent wells coated with Scl-70. In the first reaction step, diluted patient samples are incubated in the wells. In the case of positive samples, specific IgG antibodies (also IgA and IgM) will bind to the antigens. To detect the bound antibodies, a second incubation is carried out using an enzyme-labelled anti-human IgG (enzyme conjugate), which is capable of promoting a colour reaction.

Contents of the test kit:

Component	Colour	Format	Symbol
1. Microplate wells, coated with antigens: 12 microplate strips each containing 8 individual break-off wells in a frame, ready for use	---	12 x 8	
2. Calibrator 1 200 RU/ml (IgG, human), ready for use	dark red	1 x 2.0 ml	
3. Calibrator 2 20 RU/ml (IgG, human), ready for use	red	1 x 2.0 ml	
4. Calibrator 3 2 RU/ml (IgG, human), ready for use	light red	1 x 2.0 ml	
5. Positive control (IgG, human), ready for use	blue	1 x 2.0 ml	
6. Negative control (IgG, human), ready for use	green	1 x 2.0 ml	
7. Enzyme conjugate peroxidase-labelled anti-human IgG (rabbit), ready for use	green	1 x 12 ml	
8. Sample buffer ready for use	light blue	1 x 100 ml	
9. Wash buffer 10x concentrate	colourless	1 x 100 ml	
10. Chromogen/substrate solution TMB/H ₂ O ₂ , ready for use	colourless	1 x 12 ml	
11. Stop solution 0.5 M sulphuric acid, ready for use	colourless	1 x 12 ml	
12. Test instruction	---	1 booklet	
13. Protocol with target values	---	1 protocol	
 Lot description  In vitro diagnostics   Storage temperature  Unopened usable until			

Storage and stability: The test kit has to be stored at a temperature between +2°C to +8°C. Do not freeze. Unopened, all test kit components are stable until the indicated expiry date.

Waste disposal: Patient samples, calibrators, controls and incubated microplate strips should be handled as infectious waste. All reagents should be disposed of according to official regulations.



Preparation and stability of the reagents

Note: All reagents must be brought to room temperature (+18°C to +25°C) around 30 minutes before use. After first use, the reagents are stable until the indicated expiry date if stored at +2°C to +8°C and protected from contamination, unless stated otherwise below.

- **Coated wells:** Ready for use. Tear open the resealable protective wrapping of the microplate at the recesses above the grip seam. Do not open until the microplate has reached room temperature to prevent the individual strips from moistening. Immediately replace the remaining wells of a partly used microplate in the protective wrapping and tightly seal with the integrated grip seam (Do not remove the desiccant bag).
Once the protective wrapping has been opened for the first time, the wells coated with antigens can be stored in a dry place and at a temperature between +2°C and +8°C for a minimum of 4 months.
- **Calibrators and controls:** Ready for use. The reagents must be mixed thoroughly before use.
- **Enzyme conjugate:** Ready for use. The enzyme conjugate must be mixed thoroughly before use.
- **Sample buffer:** Ready for use.
- **Wash buffer:** The wash buffer is a 10x concentrate. If crystallization occurs in the concentrated buffer, warm it to 37°C and mix well before diluting. The quantity required should be removed from the bottle using a clean pipette and diluted with deionized or distilled water (1 part reagent plus 9 parts distilled water).
For example: For 1 microplate strip, 5 ml concentrate plus 45 ml water.
The ready-to-use diluted wash buffer is stable for 4 weeks when stored at +2°C to +8°C and handled properly.
- **Chromogen/substrate solution:** Ready for use. Close the bottle immediately after use, as the contents are sensitive to light. The chromogen/substrate solution must be clear on use. Do not use the solution if it is blue coloured.
- **Stop solution:** Ready for use.

Warning: Calibration and controls used have tested negative for HBsAg, anti-HCV, anti-HIV-1 and anti-HIV-2 using enzyme immunoassays or indirect immunofluorescence methods. Nonetheless, all materials should be treated as being a potential infection hazard and should be handled with care. Some of the reagents contain the toxic agent sodium azide. Avoid contact with the skin.

Preparation and stability of the patient samples

Sample material: Human serum or EDTA, heparin or citrate plasma.

Stability: Patient samples to be investigated can generally be stored at +2°C to +8°C for up to 14 days. Diluted samples should be incubated within one working day.

Sample dilution: Patient samples are diluted **1:201** in sample buffer. For example: dilute 5 µl serum in 1.0 ml sample buffer and mix well by vortexing (sample pipettes are not suitable for mixing).

NOTE: Calibrators and controls are prediluted and ready for use, do not dilute them.



Incubation

For **semiquantitative analysis** incubate **calibrator 2** along with the positive and negative controls and patient samples. For **quantitative analysis** incubate **calibrators 1, 2 and 3** along with the positive and negative controls and patient samples.

Sample incubation:
(1. step)

Transfer 100 µl calibrators, positive and negative controls or diluted patient samples into the individual microplate wells according to the pipetting protocol. Incubate for **30 minutes** at room temperature (+18°C to +25°C).

Washing:

Manual: Empty the wells and subsequently wash 3 times using 300 µl of working strength wash buffer for each wash.

Automatic: Wash reagent wells 3 times with 400 µl working strength wash buffer (program setting: e.g. TECAN Columbus Washer "Overflow Modus").

Leave the wash buffer in each well for 30 to 60 seconds per washing cycle, then empty the wells. After washing (manual and automated tests), thoroughly dispose of all liquid from the microplate by tapping it on absorbent paper with the openings facing downwards to remove all residual wash buffer.

Note: Residual liquid (> 10 µl) remaining in the reagent wells after washing can interfere with the substrate and lead to falsely low extinction values. Insufficient washing (e.g., less than 3 wash cycles, too small wash buffer volumes, or too short reaction times) can lead to falsely high extinction values.

Free positions on the microplate strip should be filled with blank wells of the same plate format as that of the parameter to be investigated.

Conjugate incubation:
(2. step)

Pipette 100 µl of enzyme conjugate (peroxidase-labelled anti-human IgG) into each of the microplate wells. Incubate for **30 minutes** at room temperature (+18°C bis 25°C).

Washing:

Empty the wells. Wash as described above.

Substrate incubation:
(3. step)

Pipette 100 µl of chromogen/substrate solution into each of the microplate wells. Incubate for **15 minutes** at room temperature (+18°C bis 25°C) protect from direct sunlight.

Stopping the reaction:

Pipette 100 µl of stop solution into each of the microplate wells in the same order and at the same speed as the chromogen/substrate solution was introduced.

Measurement:

Photometric measurement of the colour intensity should be made at a wavelength of 450 nm and a reference wavelength of between 620 nm and 650 nm **within 30 minutes of adding the stop solution**. Prior to measuring, slightly shake the micro-plate to ensure a homogeneous distribution of the solution.



Pipetting protocol

	1	2	3	4	5	6	7	8	9	10	11	12
A	C 2	P 6	P 14	P 22			C 1	P 4	P 12	P 20		
B	pos.	P 7	P 15	P 23			C 2	P 5	P 13	P 21		
C	neg.	P 8	P 16	P 24			C 3	P 6	P 14	P 22		
D	P 1	P 9	P 17				pos.	P 7	P 15	P 23		
E	P 2	P 10	P 18				neg.	P 8	P 16	P 24		
F	P 3	P 11	P 19				P 1	P 9	P 17			
G	P 4	P 12	P 20				P 2	P 10	P 18			
H	P 5	P 13	P 21				P 3	P 11	P 19			

The pipetting protocol for microtiter strips 1-4 is an example for the **semiquantitative analysis** of 24 patient samples (P 1 to P 24).

The pipetting protocol for microtiter strips 7-10 is an example for the **quantitative analysis** of 24 patient samples (P 1 to P 24).

The calibrators (C 1 to C 3), the positive (pos.) and negative (neg.) controls, and the patient samples have each been incubated in one well. The reliability of the ELISA test can be improved by duplicate determinations for each sample.

The reagent wells are break off format. Therefore, the number of tests performed can be matched to the number of samples, minimizing reagent wastage.

Both positive and negative controls serve as internal controls for the reliability of the test procedure. They should be assayed with each test run.

Calculation of results


Semiquantitative: Results can be evaluated semiquantitatively by calculating a ratio of the extinction value of the control or patient sample over the extinction value of calibrator 2. Calculate the ratio according to the following formula:

$$\frac{\text{Extinction of the control or patient sample}}{\text{Extinction of calibrator 2}} = \text{Ratio}$$

EUROIMMUN recommends interpreting results as follows:

Ratio <1.0:	negative
Ratio ≥1.0:	positive

Quantitative: The standard curve from which the concentration of antibodies in the serum samples can be taken is obtained by point-to-point plotting of the extinction values measured for the 3 calibration sera against the corresponding units (linear/linear). Use "point-to-point" plotting for calculation of the standard curve by computer. The following plot is an example of a typical calibration curve. Please do not use this curve for the determination of antibody concentrations in patient samples.



If the extinction of a serum sample lies above the value of calibrator 1 (200 RU/ml). The result should be given as ">200 RU/ml". It is recommended that the sample be re-tested at a dilution of 1:800. The result in RU/ml read from the calibration curve for this sample must then be multiplied by a factor of 4.

The upper limit of the normal range (**cut-off**) recommended by EUROIMMUN is 20 relative units (RU)/ml. EUROIMMUN recommends interpreting results as follows:

<20 RU/ml:	negative
≥20 RU/ml:	positive

For duplicate determinations the mean of the two values should be taken. If the two values deviate substantially from one another the sample should be retested.

For diagnosis, the clinical symptoms of the patient should always be taken into account alongside the serological results.

Test characteristics

Calibration: As no international reference serum exists for the quantitative detection of antibodies against Scl-70, the calibration is performed in relative units (RU)/ml. The reactivity of the Anti-Scl-70 ELISA was verified using the human reference serum CDC-ANA #9 of the "Centers for Disease Control" (Atlanta, USA).

For every group of tests performed, the extinction values of the calibrators and the relative units and/or ratios determined for the positive and negative controls must lie within the limits stated for the relevant test kit lot. A protocol containing these target values is included. If the values specified for the controls are not achieved, the test results may be inaccurate and the test should be repeated.

The activity of the enzyme used is temperature-dependent and the extinction values may vary if a thermostat is not used. The higher the room temperature (+18°C to +25°C) during substrate incubation, the greater will be the extinction values. Corresponding variations apply also to the incubation times. However, the calibrators are subject to the same influences, with the result that such variations will be largely compensated in the calculation of the result.



Antigen: The microplate wells were coated with Scl-70 purified by affinity chromatography from bovine and rabbit thymus.

Scl-70 has been recognised as the enzyme DNA-topoisomerase-I. The molecular weight of the native enzyme is 100 kDa. Originally, only a decomposition product of molecular weight 70 kDa was found in the western blot. DNA-topoisomerase-I is located in the nucleoplasm and, at a particularly high concentration, in the nucleolus. The enzyme plays a role in the replication and the transcription of the DNA double helix: it cuts the DNA chain and attaches itself to the resulting free end. There is then no need for the whole DNA molecule to rotate, which would normally not be possible, but only the region to be copied. As soon as a certain region has been replicated or transcribed, the strand is reunited and the topoisomerase released.

Linearity: The linearity of the test was investigated by assaying serial dilutions of patient sera with high antibody concentrations. The Anti-Scl-70 ELISA is linear in the measurement range 2 - 200 RU/ml.

Detection limit: The detection limit is defined as a value of three times the standard deviation of an analyte-free sample and is the smallest detectable antibody titer. The detection limit of the Anti-Scl-70 ELISA is approximately 1 RU/ml.

Cross reactivity: This ELISA showed no cross reactivity.

Interference: Haemolytic, lipaemic and icteric samples showed no influence at the result up to a concentration of 10 mg/ml for hemoglobin, 20 mg/ml for triglycerides and 0.4 mg/ml for bilirubin in this ELISA.

Reproducibility: The reproducibility of the test was investigated by determining the intra- and inter-assay coefficients of variation (CV) using 3 sera with values at different points on the calibration curve. The intra-assay CVs are based on 20 determinations and the inter-assay CVs on 4 determinations performed on 6 different days.

<i>Intra-Assay-Variation, n = 20</i>		
Serum	Mean value (RU/ml)	CV (%)
1	76	4.4
2	84	3.0
3	96	4.9

<i>Inter-Assay-Variation, n = 4 x 6</i>		
Serum	Mean value (RU/ml)	CV (%)
1	78	7.3
2	90	3.7
3	91	2.7

Reference range: The levels of the anti-Scl-70 antibodies (IgG) were analyzed with this EUROIMMUN ELISA in a panel of 206 healthy blood donors. With a cut-off of 20 RU/ml, one blood donor was positive (specificity of 99.5%).

Clinical significance

Depending on the method of testing and the individual activity of the disease, antibodies against Scl-70 have been found in 25% - 70% of patients with progressive systemic sclerosis (diffuse form). They do not occur in circumscribed scleroderma.



Literature references

1. Fritzler, M.J.: **Autoantibodies in Scleroderma**. Journal of Dermatology 20: 257-268 (1993).
2. Moore, T.L., Weiss, T.D., Neucks, S.H., Baldassare, A.R., Zuckner, J.: **Extractable nuclear antigens**. Seminars in Arthritis and Rheumatism 10: 309-318 (1981).
3. Nakamura, R.M., Tan, E.M.: **Recent advances in laboratory tests and the significance of autoantibodies to nuclear antigens in systemic rheumatic diseases**. Clinics in Laboratory Medicine 6: 41-53 (1986).
4. Reimer, G.: **Zellkernantigene bei systemischen Autoimmunkrankheiten: Molekulare Charakteristika und klinische Bedeutung**. Zentralblatt Haut- und Geschlechtskrankheiten 153: 789-800 (1987).
5. Schlumberger, W., Olbrich, S., Müller-Kunert, E., Stöcker, W.: **Autoantikörper-Diagnostik mit der Substratkombination Humane Epithelzellen (HEp-2) und Primatenleber. Differenzierung der Antikörper durch Enzymimmuntests**. EUROIMMUN-Firmenschrift (1994).
6. Schlumberger, W., Meyer, W., Proost, S., Dähnrich, C., Müller-Kunert, E., Sonnenberg, K., Olbrich, S., Stöcker, W.: **The new EUROBLot technology: Differentiation of Autoantibodies against cell nuclei**. European Journal of Clinical Chemistry and Clinical Biochemistry 33: 116 (1995).
7. Tan, E.M., Chan, E.K.L., Sullivan, K.F., Rubin, R.L.: **Antinuclear antibodies (ANAs): Diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity**. Clinical Immunology and Immunopathology 47: 121-141 (1988).
8. Tan, E.M.: **Antinuclear antibodies: Diagnostic markers for autoimmune diseases and probes for cell biology**. Advances in Immunology 44: 93-151 (1989).
9. Tomer, Y., Buskila, D., Shoenfeld, Y.: **Pathogenic significance and diagnostic value of lupus autoantibodies**. International Archives of Allergy and Immunology 100: 293-306 (1993).
10. van Venrooij, W.J., Charles, P., Maini, R.N.: **The consensus workshop for the detection of autoantibodies to intracellular antigens in rheumatic diseases**. Journal of Immunological Methods 140: 181-189 (1991).

